Grant: Doctoral Research Award: Canada Graduate Scholarships
McGill University
$105,000.00
Patient consequences following tuberculosis (TB) therapy: identifying those at risk of post-treatment relapse, reinfection, increased morbidity, and mortality in a high TB burden setting
EF 2021-22
Résumé
Tuberculosis (TB) is an airborne infectious disease affecting 10 million people worldwide. In Canada, it affects indigenous communities disproportionately, with TB rates in Inuit communities being 300 times higher than Canadian-born non-Indigenous people. Strains of TB resistant to 2 or more medications are considered "Multi-Drug Resistant" (MDR-TB). Each year, about half a million people are infected with MDR-TB globally, with catastrophic health and economic consequences, especially for marginalized communities. It is challenging to treat, requiring multiple medicines over a long duration, with potential side effects needing monitoring.
Common measures of the effectiveness of TB therapy include "Treatment failure at completion of regimen" and "recurrence within 2 years after therapy completion". However, several measures are not routinely monitored, including long-term consequences of MDR-TB, quality of life impact due to chronic lung disease, and even the outcome of death despite treatment completion. Assessing the long-term effectiveness of treatment requires follow-up data for the individuals treated. This can be challenging due to the long period required for patients to complete MDR-TB treatment. However, it is a necessary investment since we need to evaluate treatment regimens' true ability to achieve cure, and to know in which groups this occurs (by age, gender, etc.). Knowing this will help us focus on those at highest risk of unfavorable outcomes to improve their long-term care.
My proposed research study will address these gaps in our knowledge of post-treatment outcomes. The study will be based in Pakistan and include individuals who have completed treatment for MDR-TB. It will include those from a variety of settings (urban, per-urban, rural) to produce generalizable evidence to inform sound public health policy. Thus, we hope to take important steps to address this devastating illness which affects communities the world over.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
457047
Name
Khan Uzma
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Doctoral Research Awards - B
Projecttitle
Patient consequences following tuberculosis (TB) therapy: identifying those at risk of post-treatment relapse, reinfection, increased morbidity, and mortality in a high TB burden setting
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Drug-Resistant Tuberculosis; Global Health; Mortality; Pakistan; Post-Tb Lung Disease; Post-Treatment Outcomes; Quality-Of-Care; Reinfection; Relapse; Vulnerable Groups
Abstract
Tuberculosis (TB) is an airborne infectious disease affecting 10 million people worldwide. In Canada, it affects indigenous communities disproportionately, with TB rates in Inuit communities being 300 times higher than Canadian-born non-Indigenous people. Strains of TB resistant to 2 or more medications are considered "Multi-Drug Resistant" (MDR-TB). Each year, about half a million people are infected with MDR-TB globally, with catastrophic health and economic consequences, especially for marginalized communities. It is challenging to treat, requiring multiple medicines over a long duration, with potential side effects needing monitoring.
Common measures of the effectiveness of TB therapy include "Treatment failure at completion of regimen" and "recurrence within 2 years after therapy completion". However, several measures are not routinely monitored, including long-term consequences of MDR-TB, quality of life impact due to chronic lung disease, and even the outcome of death despite treatment completion. Assessing the long-term effectiveness of treatment requires follow-up data for the individuals treated. This can be challenging due to the long period required for patients to complete MDR-TB treatment. However, it is a necessary investment since we need to evaluate treatment regimens' true ability to achieve cure, and to know in which groups this occurs (by age, gender, etc.). Knowing this will help us focus on those at highest risk of unfavorable outcomes to improve their long-term care.
My proposed research study will address these gaps in our knowledge of post-treatment outcomes. The study will be based in Pakistan and include individuals who have completed treatment for MDR-TB. It will include those from a variety of settings (urban, per-urban, rural) to produce generalizable evidence to inform sound public health policy. Thus, we hope to take important steps to address this devastating illness which affects communities the world over.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Khan, Uzma
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~